<- Go Home
Comera Life Sciences Holdings, Inc.
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company’s lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Market Cap
$6.1K
Volume
54.6K
Cash and Equivalents
$1.8M
EBITDA
-$7.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$735.5K
Profit Margin
73.52%
52 Week High
$0.13
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
-0.00
Price / Earnings
-0.00
Price / Tangible Book Value
-0.00
Enterprise Value
$3.1M
Enterprise Value / EBITDA
-0.43
Operating Income
-$7.6M
Return on Equity
1629.02%
Return on Assets
-119.35
Cash and Short Term Investments
$1.8M
Debt
$561.5K
Equity
$102.3K
Revenue
$1.0M
Unlevered FCF
-$3.0M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium